Abstract
Mixed micellar nanoparticle consisting of amphotericin B (AmB) and poly styrene-block-poly ethylene oxide (PS-block-PEO) was prepared by high pressure homogenizer. Nephrotoxicity of the nanoparticle was investigated along with antifungal activity and self-aggregation status of the drug in the nanoparticle. Nephrotoxicity was markedly reduced when AmB was intravenously administered to rats as mixed micellar nanoparticle with PS-block-PEO in terms of transmission electron microscopy of tubular cells and creatinine clearance. Antifungal activity of AmB was not altered when the drug was in the form of mixed micellar nanoparticle compared to both conventional formulation and AmB micelle treated by same procedure without PS-block-PEO. Self-aggregation status of AmB molecules revealed monomeric in the mixed micellar nanoparticle with PS-block-PEO up to the therapeutic level of the drug (1-3 mM). The reduced nephrotoxicity of AmB in mixed micellar nanoparticle may be associated with the existence of the drug as monomeric form in the nanoparticle. Based on our result, formulation of AmB as mixed micellar nanoparticle with PS-block-PEO may be a promising alternative for the treatment of fungal diseases in patients who are at risk of renal dysfunction.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Barwicz, J., Christian, S., and Gruda, I., Effects of the aggregation state of amphotericin B on its toxicity to mice.Antimicrob. Agents Chemother., 36, 2310–2315 (1992).
Bolard, J., Legrand, P., Heitz, F., and Cybulska, B., One-sided action of amphotericin B on cholesterol-containing membranes is determined by its self-association in the medium.Biochemistry, 30, 5707–5715 (1991).
Brajtburg, J., Elberg, S., Travis, S. J., and Kobayashi, G. S., Treatment of murine candidiasis and cryptococcosis with amphotericin B incorporated into egg lecithin-bile salt mixed micelles.Antimicrob. Agents Chemother., 38, 294–299 (1994).
Dewhurst, P. F., Lovell, M. R., Jones, J. L, and Richards, R. W., Organization of Dispersions of a Linear Diblock Copolymer of Polystyrene and Poly(ethylene oxide) at the Air-Water InterfaceMacromolecules, 31, 7851–7864 (1998).
Ernst, C, Grange, J., Rinnert, H., Dupont, G, and Lematre, J., Structure of amphotericin B aggregates as revealed by UV and CD spectroscopies.Biopolymers, 20, 1575–1588 (1981).
Herbrecht, R., Nivoix, Y, Fohrer, C, Natarajan-Ame, S., and Letscher-Bru V, Management of systemic fungal infections: alternatives to itraconazole.J. Antimicrob. Chemother., 56 (Suppl 1), i39-i48 (2005).
Kayser, O., Lemke, A., and Hernandez-Trejo, N., The impact of nanobiotechnology on the development of new drug delivery systems.Curr. Pharm. Biotechnol., 6, 3–5 (2005).
Kleinberg, M., What is the current and future status of conventional amphotericin B?Int. J. Antimicrob. Agents, 27 (Suppl 1), 12–16(2006).
Mullen, A. B., Carter, K. C, and Baillie, A. J., Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis.Antimicrob. Agents Chemother., 41, 2089–2092(1997).
Olson, J. A., Adler-Moore, J. P., Schwartz, J., Jensen, G M., and Proffitt, R. T., Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.Antimicrob. Agents Chemother, 50, 2122–2131 (2006).
Rinnert, H., Thirion, C, Dupont, G, and Lematre J., Structural studies on aqueous and hydro alcoholic solutions of a polyene antibiotic: amphotericin B.Biopolymers, 16, 2419- 2427 (1977).
Saxena, S. and Ghosh, P. C, Biodistribution of amphotericin B when delivered through cholesterol hemisuccinate vesicles in normal and A. fumigatus infected mice.Pharm. Res., 17, 1236–1242 (2000).
Tancrede, P., Barwicz, J., Jutras, S., and Gruda, I., The effect of surfactants on the aggregation state of amphotericin B.Biochim. Biophys. Acta., 1030, 289–295 (1990).
Townsend, R. W., Zutshi, A., and Bekersky, I., The effect of surfactants on the aggregation state of amphotericin B.Drug Metab. Dispos., 29, 681–685 (2001).
Uchegbu, I. R, Pharmaceutical nanotechnology: polymeric vesicles for drug and gene delivery.Expert Opin. Drug Deliv., 3, 629–640 (2006).
Viudes, A., Peman, J., Canton, E., Ubeda, P., Lopez-Ribot, J. L., and Gobernado, M., Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death.Eur. J. Clin. Microbiol. Infect. Dis., 21, 767- 774 (2002).
Wingard, J. R., Kubilis, P., Lee, L, Yee, G, White, M., Walshe, L, Bowden, R., Anaissie, E., Hiemenz, J., and Lister, J., Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis.Clin. Infect. Dis., 29, 1402–1407 (1999).
Yamashita, K., Janout, V, Bernard, E., Armstrong, D., and Regen, S., Micelle/monomer control over the membrane- disrupting properties of an amphiphilic antibiotic.J. Am. Chem. Soc, 117, 6249–6253 (1995).
Yoo, B. K., Jalil Mian, M. A., Lee, E. S., and Han K., Synthesis of decapeptide of L-aspartic acid and benzyl-L-aspartic acid by solid phase peptide synthesis.Arch. Pharm. Res., 28, 756–760 (2005).
Yoo, B. K., Jalil Miah, M. A., Lee, E. S., and Han K., Reduced renal toxicity of nanoparticular amphotericin B micelles prepared with partially benzylated poly-L-aspartic acid.Biol. Pharm. Bull., 29, 1700–1705 (2006).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
M. A., K.H., Miah, J., Shanmugam, S. et al. Mixed micellar nanoparticle of amphotericin b and poly styrene-block-poly ethylene oxide reduces nephrotoxicity but retains antifungal activity. Arch. Pharm. Res. 30, 1344–1349 (2007). https://doi.org/10.1007/BF02980276
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02980276